Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.33 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.33 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | PGD | P52209 | 2/20 | 0.32 |
| ▸ | CDC25A | P30304 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17898563 | 0.91 | LPAR3 (0.39) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL17898557 | 0.86 | CA1 (0.38) | LPAR3LPAR1LPAR2PGK1PGK2 | |
| SCHEMBL30666129 | 0.79 | LPAR3 (0.42) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30666128 | 0.79 | LPAR3 (0.42) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL17898564 | 0.77 | LPAR3 (0.43) | LPAR3LPAR1LPAR2CDC25ACDC25B | |
| SCHEMBL17898553 | 0.74 | CA1 (0.31) | — | |
| SCHEMBL1270333 | 0.72 | LPAR3 (0.46) | LPAR3LPAR1LPAR2PGK1PGK2 | |
| SCHEMBL28933243 | 0.70 | LPAR3 (0.45) | LPAR3LPAR1LPAR2PGK1PGK2 | |
| Methane SCHEMBL7755990 | 0.70 | LPAR3 (0.45) | LPAR3LPAR1LPAR2PGK1PGK2 | |
| Phosphoric Acid SCHEMBL27874485 | 0.70 | LPAR3 (0.45) | LPAR3LPAR1LPAR2PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | LPAR3 1218/4885LPAR1 1840/4885LPAR2 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.